Literature DB >> 7595757

Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.

P E McKeever1, J Varani, S M Papadopoulos, M Wang, J P McCoy.   

Abstract

Four human astrocytic gliomas of high grade of malignancy were each evaluated in tissue and in vitro for percentages of cells expressing glial fibrillary acidic protein (GFAP), collagen type IV, laminin and fibronectin assessed by immunofluorescence with counterstaining of nuclear DNA. Percentages of cells with reticulin and cells binding fluorescein-labeled Ulex europaeus agglutinin were also assessed. In tissue, each extracellular matrix (ECM) component was associated with cells in the walls of abnormal proliferations of glioma vessels, and all four tumors had the same staining pattern. Two strikingly different patterns of conversion of gene product expression emerged during in vitro cultivation. (1). In the most common pattern, percentages of all six markers consistently shifted toward the exact phenotype of mesenchymal cells in abnormal vascular proliferations: increased reticulin, collagen type IV, laminin and fibronectin; markedly decreased glial marker GFAP and absent endothelial marker Ulex europaeus agglutinin. The simplest explanation of this constellation of changes coordinated toward expression of vascular ECM markers is that primary glioma cell cultures are overgrown by mesenchymal cells from the abnormal vascular proliferations of the original glioma. These cell cultures were tested for in situ hybridization (ISH) signals of chromosomes 7 and 10. Cells from one glioma had diploid signals. Cells from the other glioma had aneuploid signals indicating they were neoplastic; however, their signals reflected different numerical chromosomal aberrations than those common to neoplastic glia. (2). The second pattern was different. Cells with ISH chromosomal signals of neoplastic glia retained GFAP, and gained collagen type IV. Their laminin and fibronectin diminished, but persisted among a lower percentage of cells. Cloning and double immunofluorescence confirmed the presence of individual cells with glial and mesenchymal markers. A cell expressing GFAP in addition to either fibronectin, reticulin or collagen type IV is not a known constituent of glioblastoma tissue. This provides evidence of a second mechanism of conversion of gene expression in gliomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595757     DOI: 10.1007/BF01052843

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

1.  Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells.

Authors:  J P Taylor; C Cupp; A Diaz; M Chowdhury; K Khalili; S A Jimenez; S Amini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Interphase cytogenetics: a new tool for the study of genetic changes in brain tumors.

Authors:  E P Arnoldus; L B Wolters; J H Voormolen; S G van Duinen; A K Raap; M van der Ploeg; A C Peters
Journal:  J Neurosurg       Date:  1992-06       Impact factor: 5.115

3.  Biosynthesis of an unusual collagen type by human astrocytoma cells in vitro.

Authors:  K Alitalo; P Bornstein; A Vaheri; H Sage
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

4.  Biosynthesized products of cultured neuroglial cells: I. Selective release of proteins by cells from human astrocytomas.

Authors:  P E McKeever; E Quindlen; M A Banks; U Williams; P L Kornblith; S Laverson; M A Greenwood; B Smith
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

5.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

Authors:  M Hermansson; M Nistér; C Betsholtz; C H Heldin; B Westermark; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 6.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

Review 7.  Properties of human malignant glioma cells in vitro.

Authors:  J Pontén; B Westermark
Journal:  Med Biol       Date:  1978-08

8.  Products of cells cultured from gliomas. VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas.

Authors:  P E McKeever; B H Smith; J A Taren; R L Wahl; P L Kornblith; B M Chronwall
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

9.  Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein.

Authors:  R D McComb; J M Moul; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1987-11       Impact factor: 3.685

10.  Electron microscopic observations on human glioblastomas and astrocytomas maintained in organ culture systems.

Authors:  J C Sipe; M M Herman; L J Rubinstein
Journal:  Am J Pathol       Date:  1973-12       Impact factor: 4.307

View more
  2 in total

1.  Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions.

Authors:  H Bouterfa; A R Darlapp; E Klein; T Pietsch; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.

Authors:  Ana C deCarvalho; Kevin Nelson; Nancy Lemke; Norman L Lehman; Ali S Arbab; Steven Kalkanis; Tom Mikkelsen
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.